Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

NCT06468540 | Not Yet Recruiting

• 1 other identifier: IIT-2024-04-376
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.

Conditions

Central Serous Chorioretinopathy; Micropulse Laser; Photodynamic Therapy

Outcome Measures

Primary Outcomes (2)

• BCVA

  Best-corrected visual acuity using logMAR

  1 month and 6 months

• CRT

  Central retinal thickness on OCT

  1 month and 6 months

Secondary Outcomes (1)

• SFCT

  1 month and 6 months

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months, who received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy.

You may qualify if:

• Age \>18 years old.
• The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula.
• Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment.
• Patients had follow-up data before and after treatment for 1 month and at least 6 months.

You may not qualify if:

• Patients with other fundus diseases or refractive interstitial opacity.
• During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received.
• Various reasons led to incomplete patient data.

Sponsors & Collaborators

• Beijing Hospital: lead

MeSH Terms

Conditions

Central Serous Chorioretinopathy

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 8, 2024
• First Posted: June 21, 2024
• Study Start: June 15, 2024
• Primary Completion: June 15, 2025
• Study Completion: December 15, 2025
• Last Updated: June 21, 2024

Record last verified: 2024-06